| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thymus Neoplasms | 103 | 2023 | 400 | 26.760 |
Why?
|
| Thymoma | 73 | 2023 | 246 | 21.200 |
Why?
|
| Mediastinal Neoplasms | 62 | 2021 | 423 | 11.710 |
Why?
|
| Immunohistochemistry | 150 | 2023 | 7548 | 6.900 |
Why?
|
| Lung Neoplasms | 115 | 2023 | 11538 | 6.030 |
Why?
|
| Biomarkers, Tumor | 96 | 2023 | 10331 | 4.710 |
Why?
|
| Pleural Neoplasms | 20 | 2023 | 470 | 4.110 |
Why?
|
| Carcinoid Tumor | 17 | 2020 | 280 | 4.100 |
Why?
|
| Carcinoma | 26 | 2023 | 2578 | 3.970 |
Why?
|
| Mediastinum | 12 | 2021 | 268 | 3.700 |
Why?
|
| Carcinoma, Neuroendocrine | 19 | 2014 | 716 | 3.150 |
Why?
|
| Mesothelioma | 17 | 2022 | 544 | 3.000 |
Why?
|
| Thymus Gland | 11 | 2020 | 294 | 2.940 |
Why?
|
| Keratins | 29 | 2022 | 330 | 2.740 |
Why?
|
| Testicular Neoplasms | 13 | 2022 | 529 | 2.630 |
Why?
|
| Diagnosis, Differential | 77 | 2022 | 4744 | 2.450 |
Why?
|
| Seminoma | 11 | 2014 | 81 | 2.350 |
Why?
|
| Neoplasms, Glandular and Epithelial | 10 | 2018 | 519 | 2.340 |
Why?
|
| Middle Aged | 209 | 2023 | 86204 | 2.190 |
Why?
|
| Male | 252 | 2023 | 123000 | 2.080 |
Why?
|
| Humans | 360 | 2023 | 261506 | 2.040 |
Why?
|
| Lung | 19 | 2022 | 3151 | 2.000 |
Why?
|
| Adult | 191 | 2023 | 77950 | 1.970 |
Why?
|
| Mediastinal Cyst | 5 | 2021 | 22 | 1.970 |
Why?
|
| Aged | 170 | 2023 | 70117 | 1.950 |
Why?
|
| Sarcoma | 12 | 2021 | 1725 | 1.700 |
Why?
|
| Pleura | 4 | 2023 | 127 | 1.660 |
Why?
|
| Female | 218 | 2023 | 141928 | 1.640 |
Why?
|
| Adenocarcinoma | 33 | 2018 | 7789 | 1.450 |
Why?
|
| Hemangioendothelioma, Epithelioid | 3 | 2023 | 39 | 1.410 |
Why?
|
| Hemangiosarcoma | 5 | 2023 | 234 | 1.380 |
Why?
|
| Adenolymphoma | 2 | 2021 | 27 | 1.370 |
Why?
|
| Carcinoma, Mucoepidermoid | 8 | 2018 | 137 | 1.370 |
Why?
|
| Endodermal Sinus Tumor | 9 | 2019 | 47 | 1.360 |
Why?
|
| Carcinosarcoma | 7 | 2016 | 146 | 1.340 |
Why?
|
| Carcinoma, Giant Cell | 4 | 2018 | 9 | 1.290 |
Why?
|
| Neoplasm Staging | 46 | 2021 | 13658 | 1.260 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2022 | 328 | 1.240 |
Why?
|
| Cysts | 7 | 2020 | 197 | 1.220 |
Why?
|
| Terminology as Topic | 9 | 2016 | 414 | 1.210 |
Why?
|
| Neuroendocrine Tumors | 6 | 2016 | 634 | 1.130 |
Why?
|
| Carcinoma, Squamous Cell | 17 | 2023 | 5437 | 1.110 |
Why?
|
| Thymectomy | 9 | 2020 | 79 | 1.110 |
Why?
|
| Biopsy | 15 | 2023 | 3443 | 1.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 20 | 2023 | 5319 | 1.060 |
Why?
|
| Paired Box Transcription Factors | 4 | 2014 | 134 | 1.060 |
Why?
|
| Adenoma | 6 | 2020 | 716 | 1.000 |
Why?
|
| Cell Differentiation | 12 | 2019 | 4078 | 1.000 |
Why?
|
| Bronchi | 4 | 2023 | 326 | 0.980 |
Why?
|
| World Health Organization | 7 | 2023 | 316 | 0.930 |
Why?
|
| Lymphoid Tissue | 2 | 2014 | 95 | 0.930 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2014 | 223 | 0.910 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1039 | 0.910 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2021 | 332 | 0.900 |
Why?
|
| Histiocytosis, Sinus | 3 | 2022 | 86 | 0.900 |
Why?
|
| Vascular Neoplasms | 5 | 2010 | 114 | 0.890 |
Why?
|
| Adenofibroma | 2 | 2020 | 20 | 0.880 |
Why?
|
| Prognosis | 49 | 2020 | 21713 | 0.880 |
Why?
|
| Fibroma | 2 | 2021 | 85 | 0.870 |
Why?
|
| Aged, 80 and over | 51 | 2020 | 29902 | 0.870 |
Why?
|
| Giant Cell Tumors | 2 | 2021 | 33 | 0.860 |
Why?
|
| Hyalin | 2 | 2021 | 17 | 0.850 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 15 | 0.850 |
Why?
|
| Lymphoma | 5 | 2022 | 1467 | 0.840 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2013 | 74 | 0.810 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2021 | 6207 | 0.810 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2017 | 272 | 0.800 |
Why?
|
| Paraganglioma | 6 | 2014 | 170 | 0.800 |
Why?
|
| Fatal Outcome | 16 | 2015 | 829 | 0.770 |
Why?
|
| Glomus Tumor | 3 | 2016 | 27 | 0.760 |
Why?
|
| S100 Proteins | 8 | 2022 | 181 | 0.750 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2020 | 19 | 0.740 |
Why?
|
| Young Adult | 27 | 2020 | 21445 | 0.740 |
Why?
|
| Hemangioblastoma | 1 | 2020 | 22 | 0.740 |
Why?
|
| Liposarcoma | 6 | 2014 | 214 | 0.740 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2020 | 2232 | 0.730 |
Why?
|
| Follow-Up Studies | 36 | 2020 | 14889 | 0.730 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2021 | 882 | 0.710 |
Why?
|
| Pneumonectomy | 9 | 2021 | 831 | 0.710 |
Why?
|
| Antigens, CD | 8 | 2019 | 1385 | 0.710 |
Why?
|
| Predictive Value of Tests | 10 | 2021 | 4892 | 0.700 |
Why?
|
| Lung Diseases | 8 | 2010 | 717 | 0.690 |
Why?
|
| Xanthomatosis | 1 | 2019 | 21 | 0.690 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 216 | 0.690 |
Why?
|
| Neoplasms, Nerve Tissue | 1 | 2018 | 5 | 0.680 |
Why?
|
| Giant Cells | 2 | 2018 | 69 | 0.660 |
Why?
|
| Lipoma | 6 | 2014 | 89 | 0.660 |
Why?
|
| Hyperplasia | 8 | 2023 | 557 | 0.660 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 476 | 0.650 |
Why?
|
| Vimentin | 11 | 2021 | 253 | 0.630 |
Why?
|
| Adolescent | 55 | 2020 | 31252 | 0.620 |
Why?
|
| Heart Neoplasms | 3 | 2017 | 214 | 0.620 |
Why?
|
| Neoplasms, Complex and Mixed | 2 | 2016 | 43 | 0.620 |
Why?
|
| Osteoclasts | 1 | 2018 | 165 | 0.620 |
Why?
|
| Fibrosis | 4 | 2019 | 793 | 0.620 |
Why?
|
| Choristoma | 3 | 2015 | 85 | 0.610 |
Why?
|
| S100 Calcium Binding Protein G | 3 | 2013 | 50 | 0.600 |
Why?
|
| Adenoma, Pleomorphic | 4 | 2016 | 63 | 0.590 |
Why?
|
| Thoracic Cavity | 1 | 2016 | 10 | 0.580 |
Why?
|
| Hodgkin Disease | 5 | 2019 | 1429 | 0.570 |
Why?
|
| Treatment Outcome | 28 | 2021 | 32848 | 0.560 |
Why?
|
| Gene Deletion | 2 | 2020 | 1442 | 0.550 |
Why?
|
| Synaptophysin | 7 | 2016 | 79 | 0.550 |
Why?
|
| Leiomyosarcoma | 6 | 2010 | 223 | 0.550 |
Why?
|
| Carcinoma, Papillary | 3 | 2011 | 584 | 0.540 |
Why?
|
| Transcription Factors | 10 | 2023 | 5270 | 0.540 |
Why?
|
| Immunoenzyme Techniques | 16 | 2012 | 1165 | 0.530 |
Why?
|
| Mixed Tumor, Malignant | 2 | 2011 | 19 | 0.530 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2016 | 99 | 0.520 |
Why?
|
| Epithelial Cells | 5 | 2021 | 1818 | 0.510 |
Why?
|
| Sclerosis | 7 | 2010 | 84 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 5 | 2013 | 551 | 0.510 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2012 | 170 | 0.490 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2014 | 31 | 0.490 |
Why?
|
| Rhabdoid Tumor | 2 | 2013 | 110 | 0.490 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 1823 | 0.480 |
Why?
|
| Lymphatic Diseases | 3 | 2007 | 128 | 0.460 |
Why?
|
| Lymph Nodes | 7 | 2019 | 2967 | 0.460 |
Why?
|
| Survival Rate | 23 | 2020 | 12221 | 0.460 |
Why?
|
| Thymus Hyperplasia | 1 | 2012 | 4 | 0.450 |
Why?
|
| PAX8 Transcription Factor | 4 | 2014 | 55 | 0.450 |
Why?
|
| Sialadenitis | 1 | 2012 | 8 | 0.450 |
Why?
|
| Mitosis | 4 | 2013 | 615 | 0.450 |
Why?
|
| Adrenocortical Carcinoma | 2 | 2013 | 172 | 0.450 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2576 | 0.440 |
Why?
|
| Paraganglioma, Extra-Adrenal | 2 | 2007 | 31 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2013 | 1493 | 0.440 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2012 | 301 | 0.440 |
Why?
|
| Chondrosarcoma | 2 | 2011 | 216 | 0.430 |
Why?
|
| Salivary Glands | 1 | 2012 | 130 | 0.430 |
Why?
|
| Hemangioma | 3 | 2003 | 154 | 0.430 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2012 | 36 | 0.430 |
Why?
|
| Thoracic Neoplasms | 5 | 2007 | 337 | 0.420 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2012 | 95 | 0.420 |
Why?
|
| Lymphocytes | 8 | 2022 | 1234 | 0.420 |
Why?
|
| Sarcoma, Synovial | 3 | 2005 | 119 | 0.420 |
Why?
|
| Receptors, Somatostatin | 1 | 2012 | 85 | 0.420 |
Why?
|
| Adenoma, Oxyphilic | 2 | 2016 | 82 | 0.420 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 1742 | 0.410 |
Why?
|
| ErbB Receptors | 7 | 2023 | 2295 | 0.400 |
Why?
|
| Pleural Diseases | 3 | 2001 | 57 | 0.400 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 406 | 0.390 |
Why?
|
| SOXE Transcription Factors | 1 | 2011 | 29 | 0.390 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1022 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 10 | 2013 | 3981 | 0.390 |
Why?
|
| Keratin-5 | 3 | 2019 | 57 | 0.390 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 10001 | 0.390 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2023 | 2326 | 0.380 |
Why?
|
| Mediastinal Diseases | 4 | 2004 | 56 | 0.380 |
Why?
|
| Kidney Neoplasms | 4 | 2023 | 3022 | 0.380 |
Why?
|
| Salivary Gland Neoplasms | 5 | 2017 | 489 | 0.380 |
Why?
|
| Epidermal Growth Factor | 1 | 2012 | 423 | 0.380 |
Why?
|
| Peritoneal Neoplasms | 2 | 2008 | 821 | 0.380 |
Why?
|
| Carcinoma, Small Cell | 7 | 2008 | 408 | 0.370 |
Why?
|
| Oxyphil Cells | 1 | 2010 | 7 | 0.370 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 2 | 2013 | 577 | 0.370 |
Why?
|
| Cell Proliferation | 8 | 2023 | 7226 | 0.370 |
Why?
|
| Pulmonary Sclerosing Hemangioma | 1 | 2009 | 5 | 0.370 |
Why?
|
| Child | 27 | 2021 | 29154 | 0.360 |
Why?
|
| Teratoma | 6 | 2007 | 236 | 0.360 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 487 | 0.360 |
Why?
|
| Chromogranin A | 3 | 2016 | 65 | 0.350 |
Why?
|
| Retrospective Studies | 31 | 2020 | 37905 | 0.350 |
Why?
|
| Germinoma | 3 | 1999 | 84 | 0.350 |
Why?
|
| Skin Neoplasms | 4 | 2017 | 4654 | 0.350 |
Why?
|
| Myxoma | 1 | 2009 | 63 | 0.350 |
Why?
|
| Adenomyoepithelioma | 1 | 2008 | 9 | 0.340 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 650 | 0.330 |
Why?
|
| Mutation | 14 | 2023 | 15179 | 0.330 |
Why?
|
| Choriocarcinoma | 5 | 1999 | 47 | 0.330 |
Why?
|
| Histiocytes | 3 | 2022 | 94 | 0.330 |
Why?
|
| Glycoproteins | 1 | 2012 | 747 | 0.330 |
Why?
|
| Thyroid Neoplasms | 4 | 2015 | 1866 | 0.330 |
Why?
|
| Carcinoma, Adenoid Cystic | 4 | 2017 | 421 | 0.320 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2020 | 406 | 0.320 |
Why?
|
| Radiography | 15 | 2007 | 1904 | 0.320 |
Why?
|
| Pulmonary Artery | 3 | 2009 | 499 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 4975 | 0.310 |
Why?
|
| Octamer Transcription Factor-3 | 3 | 2019 | 107 | 0.310 |
Why?
|
| DNA-Binding Proteins | 4 | 2020 | 4821 | 0.310 |
Why?
|
| Calbindin 2 | 3 | 2013 | 40 | 0.300 |
Why?
|
| Mucins | 3 | 2018 | 285 | 0.290 |
Why?
|
| GATA3 Transcription Factor | 2 | 2020 | 146 | 0.290 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2007 | 262 | 0.290 |
Why?
|
| Parathyroid Neoplasms | 2 | 2005 | 185 | 0.280 |
Why?
|
| Smooth Muscle Tumor | 2 | 1997 | 9 | 0.280 |
Why?
|
| Thoracic Diseases | 1 | 2006 | 31 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2020 | 10035 | 0.270 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2005 | 6 | 0.270 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2015 | 1833 | 0.270 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2010 | 261 | 0.260 |
Why?
|
| Radiography, Thoracic | 8 | 2011 | 462 | 0.260 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2020 | 1226 | 0.260 |
Why?
|
| B-Lymphocytes | 3 | 2012 | 1294 | 0.250 |
Why?
|
| Meningioma | 3 | 2015 | 289 | 0.250 |
Why?
|
| Positron-Emission Tomography | 4 | 2020 | 2173 | 0.250 |
Why?
|
| Necrosis | 4 | 2013 | 580 | 0.250 |
Why?
|
| Neoplasms, Connective Tissue | 2 | 2011 | 20 | 0.250 |
Why?
|
| Thorax | 1 | 2006 | 213 | 0.250 |
Why?
|
| Biopsy, Needle | 4 | 2010 | 1363 | 0.250 |
Why?
|
| Leukocyte Common Antigens | 4 | 2011 | 188 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2013 | 7551 | 0.240 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 2283 | 0.240 |
Why?
|
| Lung Diseases, Fungal | 2 | 1995 | 124 | 0.240 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2015 | 436 | 0.240 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2019 | 69 | 0.240 |
Why?
|
| Medical Oncology | 2 | 2018 | 1423 | 0.240 |
Why?
|
| Histones | 1 | 2011 | 1466 | 0.240 |
Why?
|
| Epithelium | 6 | 2015 | 720 | 0.240 |
Why?
|
| Microscopy, Electron | 9 | 2005 | 600 | 0.230 |
Why?
|
| CD56 Antigen | 2 | 2016 | 83 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 4988 | 0.230 |
Why?
|
| Thyroid Nuclear Factor 1 | 4 | 2018 | 52 | 0.220 |
Why?
|
| Gene Dosage | 4 | 2014 | 829 | 0.220 |
Why?
|
| Amyloid | 1 | 2023 | 97 | 0.220 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.210 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1995 | 362 | 0.210 |
Why?
|
| Tissue Array Analysis | 7 | 2014 | 760 | 0.210 |
Why?
|
| Keratin-6 | 2 | 2014 | 39 | 0.210 |
Why?
|
| Chest Pain | 2 | 2021 | 155 | 0.210 |
Why?
|
| Antigens, CD20 | 3 | 2011 | 206 | 0.210 |
Why?
|
| Pulmonary Alveoli | 2 | 2007 | 208 | 0.210 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2014 | 123 | 0.210 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 134 | 0.210 |
Why?
|
| Histocytological Preparation Techniques | 2 | 2014 | 17 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 2403 | 0.200 |
Why?
|
| Biomarkers | 9 | 2019 | 5047 | 0.200 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 1998 | 600 | 0.200 |
Why?
|
| Diagnostic Errors | 2 | 2020 | 509 | 0.200 |
Why?
|
| Combined Modality Therapy | 8 | 2012 | 8865 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 1995 | 163 | 0.190 |
Why?
|
| Tumor Burden | 2 | 2020 | 1987 | 0.190 |
Why?
|
| Oncogenes | 3 | 2012 | 673 | 0.190 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2005 | 486 | 0.190 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2017 | 3890 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 15862 | 0.190 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 4638 | 0.180 |
Why?
|
| Myoepithelioma | 2 | 2017 | 31 | 0.180 |
Why?
|
| Dyspnea | 2 | 2021 | 416 | 0.180 |
Why?
|
| Cough | 1 | 2021 | 116 | 0.180 |
Why?
|
| Receptors, Progesterone | 2 | 2020 | 1392 | 0.180 |
Why?
|
| Melanins | 2 | 2018 | 50 | 0.180 |
Why?
|
| Mitotic Index | 1 | 2020 | 162 | 0.180 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 27 | 0.180 |
Why?
|
| Child, Preschool | 13 | 2011 | 16273 | 0.180 |
Why?
|
| Rhabdomyoma | 2 | 2004 | 23 | 0.180 |
Why?
|
| Dirofilariasis | 1 | 1999 | 5 | 0.170 |
Why?
|
| Amyloidosis | 1 | 2001 | 176 | 0.170 |
Why?
|
| Desmosomes | 2 | 2012 | 28 | 0.170 |
Why?
|
| Perilipin-2 | 1 | 2018 | 31 | 0.170 |
Why?
|
| Cell Nucleus | 4 | 2013 | 1620 | 0.170 |
Why?
|
| Pigmentation | 1 | 2018 | 47 | 0.170 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2011 | 199 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2000 | 299 | 0.160 |
Why?
|
| Homozygote | 1 | 2020 | 717 | 0.160 |
Why?
|
| Neoplasm Metastasis | 8 | 2010 | 5112 | 0.160 |
Why?
|
| Plasmacytoma | 2 | 1998 | 111 | 0.160 |
Why?
|
| Plasma Cells | 3 | 2001 | 192 | 0.160 |
Why?
|
| Fibromatosis, Aggressive | 1 | 1999 | 109 | 0.160 |
Why?
|
| Calculi | 1 | 1997 | 14 | 0.150 |
Why?
|
| Texas | 4 | 2012 | 6311 | 0.150 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 1998 | 108 | 0.150 |
Why?
|
| Carcinoma, Medullary | 1 | 1999 | 248 | 0.150 |
Why?
|
| Granuloma, Plasma Cell | 1 | 1997 | 38 | 0.150 |
Why?
|
| Actins | 5 | 1998 | 608 | 0.140 |
Why?
|
| alpha-Fetoproteins | 4 | 1997 | 237 | 0.140 |
Why?
|
| 12E7 Antigen | 2 | 2013 | 11 | 0.140 |
Why?
|
| Ependymoma | 1 | 1998 | 242 | 0.140 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2015 | 16 | 0.140 |
Why?
|
| Neurilemmoma | 1 | 1997 | 127 | 0.140 |
Why?
|
| Antigens, Neoplasm | 4 | 2014 | 1506 | 0.140 |
Why?
|
| Leprosy, Borderline | 1 | 1995 | 1 | 0.140 |
Why?
|
| Pathology, Surgical | 2 | 2019 | 81 | 0.140 |
Why?
|
| Leprosy, Tuberculoid | 1 | 1995 | 11 | 0.140 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2001 | 73 | 0.130 |
Why?
|
| Leprosy, Lepromatous | 1 | 1995 | 12 | 0.130 |
Why?
|
| Cell Lineage | 2 | 2016 | 668 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 6009 | 0.130 |
Why?
|
| ras Proteins | 4 | 2015 | 770 | 0.130 |
Why?
|
| Phenotype | 4 | 2016 | 6295 | 0.130 |
Why?
|
| Pulmonary Blastoma | 2 | 2011 | 18 | 0.130 |
Why?
|
| Immunophenotyping | 2 | 2019 | 1681 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2015 | 2488 | 0.130 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 1995 | 41 | 0.130 |
Why?
|
| Spinal Neoplasms | 2 | 1997 | 631 | 0.130 |
Why?
|
| Hemangioma, Cavernous | 1 | 1995 | 27 | 0.130 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2015 | 86 | 0.130 |
Why?
|
| Hemangioma, Capillary | 1 | 1995 | 35 | 0.130 |
Why?
|
| Survival Analysis | 9 | 2018 | 9180 | 0.130 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2015 | 98 | 0.130 |
Why?
|
| Anaphase | 1 | 2015 | 44 | 0.130 |
Why?
|
| SOXF Transcription Factors | 1 | 2014 | 34 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.130 |
Why?
|
| Immunochemistry | 1 | 2014 | 61 | 0.130 |
Why?
|
| Glypicans | 1 | 2014 | 51 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2020 | 1301 | 0.130 |
Why?
|
| Decidua | 2 | 1998 | 154 | 0.130 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1994 | 34 | 0.120 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2014 | 29 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 1 | 2001 | 895 | 0.120 |
Why?
|
| Leiomyoma | 1 | 1995 | 145 | 0.120 |
Why?
|
| Lymphatic Metastasis | 4 | 2010 | 4844 | 0.120 |
Why?
|
| Prednisone | 2 | 2013 | 984 | 0.120 |
Why?
|
| Chordoma | 1 | 1995 | 163 | 0.120 |
Why?
|
| Granuloma, Giant Cell | 1 | 1993 | 17 | 0.120 |
Why?
|
| Chromogranins | 5 | 2005 | 84 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2015 | 249 | 0.120 |
Why?
|
| Neoplasm Proteins | 6 | 2014 | 3230 | 0.120 |
Why?
|
| Antibodies | 2 | 2011 | 838 | 0.120 |
Why?
|
| MART-1 Antigen | 1 | 2013 | 105 | 0.110 |
Why?
|
| Purines | 1 | 2015 | 273 | 0.110 |
Why?
|
| Bronchial Neoplasms | 1 | 1994 | 79 | 0.110 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2014 | 153 | 0.110 |
Why?
|
| Opportunistic Infections | 1 | 1995 | 223 | 0.110 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 68 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2014 | 236 | 0.110 |
Why?
|
| Inhibins | 1 | 2013 | 128 | 0.110 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 318 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2012 | 1064 | 0.110 |
Why?
|
| Microtubules | 1 | 2014 | 270 | 0.110 |
Why?
|
| Epiregulin | 1 | 2012 | 14 | 0.110 |
Why?
|
| EGF Family of Proteins | 1 | 2012 | 28 | 0.110 |
Why?
|
| Hamartoma | 1 | 1993 | 115 | 0.110 |
Why?
|
| Amphiregulin | 1 | 2012 | 32 | 0.110 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2013 | 160 | 0.110 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2013 | 44 | 0.110 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 152 | 0.110 |
Why?
|
| Trace Elements | 1 | 2012 | 33 | 0.110 |
Why?
|
| Thyroidectomy | 1 | 2015 | 486 | 0.110 |
Why?
|
| Respiratory Aspiration | 1 | 2012 | 30 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2008 | 1085 | 0.110 |
Why?
|
| Glycogen | 1 | 2012 | 80 | 0.110 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 2086 | 0.110 |
Why?
|
| Transcriptome | 3 | 2020 | 1859 | 0.110 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2012 | 24 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 3 | 2004 | 3976 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 94 | 0.110 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 87 | 0.110 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2015 | 690 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 2864 | 0.100 |
Why?
|
| Wood | 1 | 1991 | 18 | 0.100 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 354 | 0.100 |
Why?
|
| Dust | 1 | 1991 | 39 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 534 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 755 | 0.100 |
Why?
|
| Metaplasia | 1 | 2013 | 383 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 441 | 0.100 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 58 | 0.100 |
Why?
|
| Respiratory Mucosa | 1 | 2012 | 206 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.100 |
Why?
|
| Infant | 9 | 2007 | 13310 | 0.100 |
Why?
|
| Titanium | 1 | 1991 | 61 | 0.100 |
Why?
|
| Policy Making | 1 | 2011 | 85 | 0.100 |
Why?
|
| Antigens, CD34 | 3 | 2013 | 593 | 0.100 |
Why?
|
| Foreign Bodies | 1 | 2012 | 145 | 0.090 |
Why?
|
| Occupational Diseases | 1 | 1991 | 130 | 0.090 |
Why?
|
| Loss of Heterozygosity | 1 | 2012 | 602 | 0.090 |
Why?
|
| Pericarditis | 1 | 2011 | 61 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2005 | 2341 | 0.090 |
Why?
|
| Malacoplakia | 1 | 1989 | 4 | 0.090 |
Why?
|
| Carcinoma, Embryonal | 3 | 1999 | 29 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2011 | 74 | 0.090 |
Why?
|
| Brain Neoplasms | 3 | 2018 | 4849 | 0.090 |
Why?
|
| Mucin-1 | 2 | 2003 | 127 | 0.090 |
Why?
|
| Laryngeal Neoplasms | 1 | 1993 | 518 | 0.090 |
Why?
|
| Observer Variation | 1 | 2011 | 671 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 3869 | 0.090 |
Why?
|
| Delphi Technique | 1 | 2010 | 210 | 0.090 |
Why?
|
| Phosphoproteins | 1 | 2015 | 1152 | 0.090 |
Why?
|
| Colonic Diseases | 1 | 1989 | 71 | 0.090 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 488 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 984 | 0.090 |
Why?
|
| Myasthenia Gravis | 1 | 1990 | 99 | 0.090 |
Why?
|
| Iron | 1 | 2012 | 376 | 0.090 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1991 | 323 | 0.090 |
Why?
|
| Checklist | 1 | 2010 | 122 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2015 | 2045 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 8873 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2015 | 1863 | 0.080 |
Why?
|
| Inflammation | 1 | 1999 | 2522 | 0.080 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1991 | 285 | 0.080 |
Why?
|
| Estrogen Receptor beta | 1 | 2009 | 155 | 0.080 |
Why?
|
| Immunoglobulin lambda-Chains | 2 | 2001 | 41 | 0.080 |
Why?
|
| Carcinoembryonic Antigen | 3 | 2001 | 222 | 0.080 |
Why?
|
| Classification | 1 | 2008 | 41 | 0.080 |
Why?
|
| Age Distribution | 2 | 2009 | 698 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 5159 | 0.080 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 101 | 0.080 |
Why?
|
| Appendicitis | 1 | 1990 | 169 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2010 | 201 | 0.080 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2010 | 249 | 0.080 |
Why?
|
| Penile Neoplasms | 1 | 1990 | 161 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 558 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 2 | 2005 | 252 | 0.080 |
Why?
|
| Skin Diseases | 1 | 1991 | 349 | 0.080 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2007 | 6 | 0.080 |
Why?
|
| Lithiasis | 1 | 2007 | 7 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 348 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2011 | 561 | 0.080 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 5767 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 1331 | 0.080 |
Why?
|
| Algorithms | 2 | 2016 | 3890 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 1 | 1992 | 966 | 0.070 |
Why?
|
| Sex Factors | 2 | 2011 | 2139 | 0.070 |
Why?
|
| Alkaline Phosphatase | 2 | 1997 | 207 | 0.070 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2006 | 38 | 0.070 |
Why?
|
| Orchiectomy | 1 | 2007 | 214 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 404 | 0.070 |
Why?
|
| Adrenal Cortex | 1 | 2006 | 35 | 0.070 |
Why?
|
| Epidermal Cyst | 1 | 2007 | 46 | 0.070 |
Why?
|
| Liver Neoplasms | 3 | 1998 | 4557 | 0.070 |
Why?
|
| Physicians | 2 | 2014 | 882 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2014 | 1270 | 0.070 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2006 | 323 | 0.070 |
Why?
|
| Nuclear Proteins | 4 | 2014 | 3343 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2007 | 330 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 92 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.070 |
Why?
|
| Adenocarcinoma, Clear Cell | 2 | 2016 | 178 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 3001 | 0.070 |
Why?
|
| Doxorubicin | 1 | 2013 | 3005 | 0.070 |
Why?
|
| Cisplatin | 1 | 2013 | 2432 | 0.070 |
Why?
|
| Rhabdomyosarcoma | 3 | 2010 | 341 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2015 | 14289 | 0.070 |
Why?
|
| Fibroblasts | 1 | 2012 | 1682 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 1516 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 1990 | 526 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 1664 | 0.060 |
Why?
|
| Carcinoma, Acinar Cell | 2 | 2016 | 84 | 0.060 |
Why?
|
| Liver | 2 | 1994 | 2961 | 0.060 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2005 | 157 | 0.060 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2023 | 973 | 0.060 |
Why?
|
| Animals | 4 | 2016 | 59536 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2009 | 701 | 0.060 |
Why?
|
| Precancerous Conditions | 2 | 2010 | 1058 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1265 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2004 | 36 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2010 | 1910 | 0.060 |
Why?
|
| Calcinosis | 1 | 2007 | 423 | 0.060 |
Why?
|
| CD57 Antigens | 2 | 2000 | 20 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 1021 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1162 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 1995 | 2138 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 3639 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2819 | 0.060 |
Why?
|
| Recurrence | 1 | 2011 | 4758 | 0.060 |
Why?
|
| CD27 Ligand | 1 | 2023 | 25 | 0.060 |
Why?
|
| HIV Infections | 2 | 1995 | 2134 | 0.060 |
Why?
|
| Melanoma | 2 | 1997 | 5317 | 0.060 |
Why?
|
| Smoking | 4 | 2020 | 2440 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 4971 | 0.050 |
Why?
|
| Testis | 1 | 2007 | 717 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2007 | 545 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 3719 | 0.050 |
Why?
|
| Age Factors | 1 | 2011 | 5377 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2330 | 0.050 |
Why?
|
| Infarction | 1 | 2001 | 31 | 0.050 |
Why?
|
| Cytoplasm | 2 | 2009 | 652 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 340 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 2231 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 1989 | 1390 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2014 | 2508 | 0.050 |
Why?
|
| Dermis | 1 | 2001 | 65 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2003 | 355 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia | 1 | 2001 | 57 | 0.050 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2001 | 61 | 0.050 |
Why?
|
| Desmin | 2 | 1998 | 63 | 0.050 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2001 | 38 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2023 | 14551 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 1217 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 2638 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 1053 | 0.040 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2001 | 156 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2358 | 0.040 |
Why?
|
| Cell Size | 1 | 1999 | 136 | 0.040 |
Why?
|
| Ganglioneuroblastoma | 1 | 1998 | 8 | 0.040 |
Why?
|
| Pathologists | 1 | 2019 | 91 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2007 | 1350 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 1999 | 276 | 0.040 |
Why?
|
| Placental Lactogen | 1 | 1997 | 7 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 4298 | 0.040 |
Why?
|
| Disease Progression | 4 | 2013 | 6682 | 0.040 |
Why?
|
| Lipomatosis | 1 | 1997 | 24 | 0.040 |
Why?
|
| Melanoma-Specific Antigens | 1 | 1997 | 82 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 1997 | 130 | 0.040 |
Why?
|
| Phosphorus | 1 | 1997 | 65 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1997 | 220 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 726 | 0.040 |
Why?
|
| Asthma | 1 | 2005 | 871 | 0.040 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 1997 | 75 | 0.040 |
Why?
|
| Splenic Neoplasms | 1 | 1997 | 119 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2001 | 712 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 315 | 0.040 |
Why?
|
| Adipose Tissue | 3 | 1997 | 769 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2014 | 3536 | 0.030 |
Why?
|
| Endometriosis | 1 | 1998 | 214 | 0.030 |
Why?
|
| Back | 1 | 1995 | 45 | 0.030 |
Why?
|
| Buttocks | 1 | 1995 | 24 | 0.030 |
Why?
|
| Groin | 1 | 1995 | 74 | 0.030 |
Why?
|
| Mycobacterium leprae | 1 | 1995 | 16 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2015 | 169 | 0.030 |
Why?
|
| Thalassemia | 1 | 1995 | 26 | 0.030 |
Why?
|
| Blastomycosis | 1 | 1995 | 17 | 0.030 |
Why?
|
| Histocytochemistry | 1 | 1995 | 185 | 0.030 |
Why?
|
| Perineum | 1 | 1995 | 107 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 614 | 0.030 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 1995 | 52 | 0.030 |
Why?
|
| Coccidioidomycosis | 1 | 1995 | 32 | 0.030 |
Why?
|
| Intermediate Filament Proteins | 1 | 1995 | 81 | 0.030 |
Why?
|
| Breast Neoplasms | 4 | 2010 | 15694 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1997 | 222 | 0.030 |
Why?
|
| Histoplasmosis | 1 | 1995 | 74 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 1995 | 104 | 0.030 |
Why?
|
| Cryptococcosis | 1 | 1995 | 63 | 0.030 |
Why?
|
| Cell Division | 1 | 1999 | 2489 | 0.030 |
Why?
|
| Receptors, Vasoactive Intestinal Polypeptide, Type I | 1 | 2014 | 8 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2007 | 6869 | 0.030 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1994 | 44 | 0.030 |
Why?
|
| Enkephalin, Leucine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 65 | 0.030 |
Why?
|
| Epothilones | 1 | 2014 | 54 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 1993 | 30 | 0.030 |
Why?
|
| Keratin-7 | 2 | 2005 | 52 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 1994 | 56 | 0.030 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1994 | 151 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1995 | 339 | 0.030 |
Why?
|
| Fungi | 1 | 1995 | 145 | 0.030 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1994 | 140 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1996 | 492 | 0.030 |
Why?
|
| Genes, ras | 1 | 1996 | 667 | 0.030 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1994 | 74 | 0.030 |
Why?
|
| Pregnancy | 3 | 1998 | 7573 | 0.030 |
Why?
|
| Granuloma | 1 | 1994 | 154 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 324 | 0.030 |
Why?
|
| Aspergillosis | 1 | 1995 | 246 | 0.030 |
Why?
|
| Dysgerminoma | 1 | 1992 | 42 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1997 | 489 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2011 | 6550 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2014 | 392 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2014 | 229 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2009 | 1648 | 0.030 |
Why?
|
| Asbestos | 1 | 1992 | 35 | 0.030 |
Why?
|
| Kidney | 1 | 2001 | 2146 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2018 | 1335 | 0.030 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2013 | 245 | 0.030 |
Why?
|
| Melphalan | 1 | 1995 | 834 | 0.030 |
Why?
|
| Genes, p53 | 1 | 1996 | 1090 | 0.030 |
Why?
|
| Electron Probe Microanalysis | 1 | 1991 | 5 | 0.030 |
Why?
|
| Cushing Syndrome | 1 | 2012 | 70 | 0.030 |
Why?
|
| Pericardium | 1 | 2013 | 157 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2007 | 3578 | 0.030 |
Why?
|
| Synovial Membrane | 1 | 1991 | 41 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 1991 | 69 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 2011 | 13 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2011 | 10 | 0.020 |
Why?
|
| Pulmonary Surfactant-Associated Protein B | 1 | 2011 | 14 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2011 | 136 | 0.020 |
Why?
|
| Formaldehyde | 1 | 2011 | 114 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 980 | 0.020 |
Why?
|
| Health Policy | 1 | 2014 | 291 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2013 | 183 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2011 | 226 | 0.020 |
Why?
|
| Calcium | 1 | 1997 | 1537 | 0.020 |
Why?
|
| Splenomegaly | 1 | 1991 | 158 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 3842 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 1991 | 149 | 0.020 |
Why?
|
| Sweat Gland Neoplasms | 1 | 1991 | 71 | 0.020 |
Why?
|
| HIV | 1 | 1992 | 229 | 0.020 |
Why?
|
| Pneumoconiosis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Heart Atria | 1 | 2013 | 352 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2010 | 89 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 2594 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 75 | 0.020 |
Why?
|
| Nanog Homeobox Protein | 1 | 2010 | 65 | 0.020 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2010 | 104 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1996 | 3203 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 5539 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1992 | 288 | 0.020 |
Why?
|
| Erdheim-Chester Disease | 1 | 2010 | 53 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1992 | 694 | 0.020 |
Why?
|
| Genetic Techniques | 1 | 2010 | 130 | 0.020 |
Why?
|
| Anemia | 1 | 1995 | 689 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 2738 | 0.020 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1999 | 51 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 1990 | 429 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 5178 | 0.020 |
Why?
|
| Collagen | 1 | 1992 | 752 | 0.020 |
Why?
|
| Bronchiolitis | 1 | 2010 | 126 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2002 | 3552 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2011 | 731 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2084 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 360 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 2450 | 0.020 |
Why?
|
| Integrins | 1 | 2009 | 262 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2010 | 702 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 1439 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 750 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 1994 | 941 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Pneumonia | 1 | 2012 | 751 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2006 | 344 | 0.020 |
Why?
|
| Carotid Body Tumor | 1 | 2006 | 18 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1546 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1990 | 2307 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 660 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 1163 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2006 | 133 | 0.020 |
Why?
|
| Base Sequence | 1 | 1992 | 4917 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 7702 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 1995 | 8223 | 0.020 |
Why?
|
| Etoposide | 1 | 2006 | 870 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 6089 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 1143 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2018 | 3341 | 0.020 |
Why?
|
| Mammography | 1 | 2010 | 1010 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 6150 | 0.010 |
Why?
|
| Methotrexate | 1 | 2006 | 999 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 1237 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 967 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 551 | 0.010 |
Why?
|
| Testosterone | 1 | 2007 | 619 | 0.010 |
Why?
|
| Factor XIII | 1 | 2001 | 8 | 0.010 |
Why?
|
| Palliative Care | 1 | 2013 | 2037 | 0.010 |
Why?
|
| United States | 1 | 2018 | 15433 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2003 | 467 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2006 | 1353 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 170 | 0.010 |
Why?
|
| Remission Induction | 1 | 2007 | 3569 | 0.010 |
Why?
|
| Cystectomy | 1 | 2004 | 623 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 3570 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 3260 | 0.010 |
Why?
|
| Zollinger-Ellison Syndrome | 1 | 1998 | 7 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1998 | 153 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 1998 | 141 | 0.010 |
Why?
|
| Monocytes | 1 | 2001 | 788 | 0.010 |
Why?
|
| Pulmonary Emphysema | 1 | 1997 | 145 | 0.010 |
Why?
|
| Myoglobin | 1 | 1995 | 116 | 0.010 |
Why?
|
| Skin | 1 | 2001 | 1259 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2001 | 1085 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 34495 | 0.010 |
Why?
|
| Point Mutation | 1 | 1996 | 769 | 0.010 |
Why?
|
| Infant, Low Birth Weight | 1 | 1994 | 181 | 0.010 |
Why?
|
| Infant, Premature, Diseases | 1 | 1994 | 245 | 0.010 |
Why?
|
| Gestational Age | 1 | 1994 | 1069 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 17523 | 0.010 |
Why?
|
| Infant, Premature | 1 | 1994 | 787 | 0.010 |
Why?
|